Back to journals
Academic Journal

Nature Mental Health

6 Papers Indexed in Blossom

Data updated

Research Footprint

Nature Mental Health has 6 tracked papers indexed in Blossom (2023–2026) from 55 authors, most often covering Psilocybin, Ibogaine and Ketamine, across Depressive Disorders, Anxiety Disorders and Neuroimaging & Brain Measures.

Published Papers

Paywallmeta

A living systematic review, meta-analysis and open-data resource of randomized controlled trials of psilocybin treatment for symptoms of depression

This systematic review and meta-analysis (s=15) of randomised controlled trials found that psilocybin-assisted therapy was linked to a larger reduction in depression scores than control conditions. The review included 801 participants overall, with 585 in the main analysis, but many studies were small or at risk of bias.

Published
Journal
Nature Mental Health
Authors
Singleton, S. P., Sevchik, B. L., Lahey, A., Cuijpers, P., Harrer, M., Jones, M. T., Nayak, S. M., Strain, E. C., Vandekar, S. N., Dworkin, R. H., Scott, J. C., Satterthwaite, T. D.
Paywallindividual

Magnesium-ibogaine therapy effects on cortical oscillations and neural complexity in veterans with traumatic brain injury

This analysis of an open-label observational study (n=30) found that magnesium-ibogaine therapy in combat veterans with traumatic brain injury (TBI) led to slower brain wave patterns and reduced neural complexity on EEG, which correlated with improvements in PTSD, anxiety, and cognitive function at one-month follow-up.

Published
Journal
Nature Mental Health
Authors
Lissemore, J. I., Chaiken, A., Keller, C. J., Williams, N. R., Cherian, K. N., Buchanan, D., Espil, F., Keynan, J. N., Sridhar, M., Rolle, C. E., Saggar, M.
Paywallindividual

Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer

This pooled analysis of two Phase II RCTs (n=79) evaluates psilocybin-assisted psychotherapy (PAP/PAT) for cancer-related distress. PAT significantly improves anxiety, depression, interpersonal sensitivity, hostility, obsession-compulsion, and somatization without inducing lasting phobia, paranoia, or psychosis.

Published
Journal
Nature Mental Health
Authors
Petridis, P. D., Grinband, J., Agin-Liebes, G., Kinslow, C. J., Zeifman, R. J., Bogenschutz, M. P., Griffiths, R. R., Ross, S.
Paywallmeta

Optimizing real-world benefit and risk of new psychedelic medications: the need for innovative postmarket surveillance

This commentary (2024) highlights the promising results from late-phase clinical trials on psychedelic-assisted psychotherapy, suggesting imminent FDA approval and wider adoption in the USA. However, it emphasizes the crucial need for postmarket surveillance to ensure real-world benefits are maximized, and potential risks are mitigated. Without proper surveillance, there's a risk of incorrect conclusions, such as attributing adverse events to illicit psychedelics. Effective surveillance programs should monitor access, safety, and effectiveness across various domains, but current data systems are inadequate, necessitating intentionally designed surveillance mechanisms.

Published
Journal
Nature Mental Health
Authors
Black, J. C., Monte, A. A., Dasgupta, N., Jewell, J. S., Rockhill, K. M., Olson, R. A., Dart, R. C.
Paywallmeta

Exploring mechanisms of psychedelic action using neuroimaging

This review (2024) discusses the pivotal role of neuroimaging in modern psychedelic research, providing insights into the acute and longer-term therapeutic effects of these substances. Evidence from fMRI, PET, and MEG/EEG studies informs computational models, offering a comprehensive understanding of the effects of psychedelics on human consciousness as well as supporting the advancement of psychedelic therapies.

Published
Journal
Nature Mental Health
Authors
Erritzoe, D., Timmermann, C., Godfrey, K., Castro-Rodrigues, P., Peill, J., Carhart-Harris, R. L., Nutt, D. J., Wall, M. B.
Open Accessindividual

Trial of Ketamine Masked by Surgical Anesthesia in Depressed Patients

This triple-masked, randomised, placebo-controlled trial (n=40) of adults with major depressive disorder (MDD) found no short-term effect on depression severity (measured by MADRS) after a single dose of intravenous ketamine (35mg/70kg) compared to placebo (saline) during anaesthesia for routine surgery.

Published
Journal
Nature Mental Health
Authors
Lii, T. R., Smith, A. E., Flohr, J. R., Okada, R. L., Nyongesa, C. A., Cianfichi, L. J., Hack, L. M., Schatzberg, A. F., Heifets, B. D.

Quick Facts

Papers Indexed
6
h-Index
13
Open Access
No
Publisher
Springer Nature
Country
United Kingdom
Website
Visit